a. moderate or severe acute respiratory failure, or requiring non-invasive ventilation or oxygen, or with spo2 \<92% or tachypnea (respiratory rate ≥30 breaths/minute); b. serious and uncontrolled preexisting organ insufficiency, which prevents participation in the study by the investigator's judgment; c. diagnosis of previous asthma using inhaled or oral corticosteroids in the last four weeks; d. previous use, in the last ten days of randomization, of inhaled, oral or intravenous corticosteroids; hydroxychloroquine and dewormers. e. previous diagnosis of chronic obstructive pulmonary disease, even when not using any inhaled medication; f. pregnant or lactating women; g. use of any investigational or unrecorded product within the 3 month period or the 5 half-lives period prior to the baseline period, whichever is longer; h. any condition that, in the investigator's opinion, could compromise the participant's safety or adherence to the study protocol.

a. moderate or severe acute respiratory failure, or requiring non-invasive ventilation or oxygen, or with spo2 \<92% or tachypnea (respiratory rate ≥30 breaths/minute); b. serious and uncontrolled preexisting organ insufficiency, which prevents participation in the study by the investigator's judgment; c. diagnosis of previous asthma using inhaled or oral corticosteroids in the last four weeks; d. previous use, in the last ten days of randomization, of inhaled, oral or intravenous corticosteroids; hydroxychloroquine and dewormers. e. previous diagnosis of chronic obstructive pulmonary disease, even when not using any inhaled medication; f. pregnant or lactating women; g. use of any investigational or unrecorded product within the 3 month period or the 5 half-lives period prior to the baseline period, whichever is longer; h. any condition that, in the investigator's opinion, could compromise the participant's safety or adherence to the study protocol.

a. moderate or severe acute respiratory failure, or requiring non-invasive ventilation or oxygen, or with spo2 <92% or tachypnea (respiratory rate ≥30 breaths/minute); b. serious and uncontrolled preexisting organ insufficiency, which prevents participation in the study by the investigator's judgment; c. diagnosis of previous asthma using inhaled or oral corticosteroids in the last four weeks; d. previous use, in the last ten days of randomization, of inhaled, oral or intravenous corticosteroids; hydroxychloroquine and dewormers. e. previous diagnosis of chronic obstructive pulmonary disease, even when not using any inhaled medication; f. pregnant or lactating women; g. use of any investigational or unrecorded product within the 3 month period or the 5 half-lives period prior to the baseline period, whichever is longer; h. any condition that, in the investigator's opinion, could compromise the participant's safety or adherence to the study protocol.

a. moderate or severe acute respiratory failure, or requiring non-invasive ventilation or oxygen, or with spo2 <92% or tachypnea (respiratory rate ≥30 breaths/minute); b. serious and uncontrolled preexisting organ insufficiency, which prevents participation in the study by the investigator's judgment; c. diagnosis of previous asthma using inhaled or oral corticosteroids in the last four weeks; d. previous use, in the last ten days of randomization, of inhaled, oral or intravenous corticosteroids; hydroxychloroquine and dewormers. e. previous diagnosis of chronic obstructive pulmonary disease, even when not using any inhaled medication; f. pregnant or lactating women; g. use of any investigational or unrecorded product within the 3 month period or the 5 half-lives period prior to the baseline period, whichever is longer; h. any condition that, in the investigator's opinion, could compromise the participant's safety or adherence to the study protocol.